CSTL Castle Biosciences
- 21.530
- +1.190+5.85%
- 21.530
- 0.0000.00%
Castle Biosciences News
Castle Biosciences(CSTL.US) Officer Sells US$22,642.73 in Common Stock
$Castle Biosciences(CSTL.US)$ Officer MAETZOLD DEREK J sold 1,126 shares of common stock on Apr 23, 2024 at an average price of $20.109 for a total value of $22,642.73.Source: Announcement What is sta
We're Not Worried About Castle Biosciences' (NASDAQ:CSTL) Cash Burn
Castle Biosciences(CSTL.US) Officer Sells US$106.02K in Common Stock
$Castle Biosciences(CSTL.US)$ Officer MAETZOLD DEREK J sold 5,210 shares of common stock on Apr 12, 2024 at an average price of $20.35 for a total value of $106.02K.Source: Announcement What is statem
Form 144 | Castle Biosciences(CSTL.US) Officer Proposes to Sell 381.3K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 12, $Castle Biosciences(CSTL.US)$ Officer Derek Maetzold intends to sell 19,008 shares of its common stock on Apr 12, with a total market value of approximately $381.3K.
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2024,
Castle Biosciences(CSTL.US) Director Sells US$49,087.2 in Common Stock
$Castle Biosciences(CSTL.US)$ Director BRADBURY DANIEL sold 2,400 shares of common stock on Apr 8, 2024 at an average price of $20.453 for a total value of $49,087.2.Source: Announcement What is state
Castle Biosciences Celebrates Esophageal Cancer Awareness Month Through Advocacy and Educational Collaborations
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, recognizes the importance of Esophageal Cancer Awareness Month and is providing its support of key programs and initiatives throughout the month of April.
Castle Biosciences' Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
CastleBiosciences--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that, for the second year in a row, its chief financial officer, Frank Stokes, has been selected as a Top 25 CFO of Houston by TOP CFOs (formerly Finance & Investing).
Castle Biosciences(CSTL.US) Director Sells US$441.85K in Common Stock
$Castle Biosciences(CSTL.US)$ Director BRADBURY DANIEL sold 20,923 shares of common stock on Apr 4, 5, 2024 at an average price of $21.12 for a total value of $441.85K.Source: Announcement What is sta
Castle Biosciences Insider Sold Shares Worth $441,853, According to a Recent SEC Filing
Daniel Bradbury, Director, on April 04, 2024, sold 20,923 shares in Castle Biosciences (CSTL) for $441,853. Following the Form 4 filing with the SEC, Bradbury has control over a total of 23,423 shares
Castle Biosciences(CSTL.US) Officer Sells US$137.49K in Common Stock
$Castle Biosciences(CSTL.US)$ Officer MAETZOLD DEREK J sold 6,336 shares of Common Stock on Apr 3, 2024 at an average price of $21.7 for a total value of $137.49K.Source: Announcement What is statemen
What Makes Castle Bioscience (CSTL) a Prospective Investment?
Form 144 | Castle Biosciences(CSTL.US) Insider Proposes to Sell 990.76K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 4, $Castle Biosciences(CSTL.US)$ Insider Daniel Bradbury intends to sell 46,646 shares of its common stock on Apr 4, with a total market value of approximately $990.76K.
Castle Biosciences Plans To Share New Data At The 20Th European Association Of Dermato-Oncology Congress
Castle Biosciences Plans To Share New Data At The 20Th European Association Of Dermato-Oncology Congress
Presentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx-Melanoma and DecisionDx-SCC Tests on the Management of Patients With Skin Cancer
If choosing to use a molecular test to rule-out a sentinel lymph node biopsy (SLNB) in patients diagnosed with melanoma, it is important to show that patients foregoing an SLNB have low risk outcomes; Castle's poster on
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company's executive management is scheduled to present a company overview at
Castle Biosciences Secures Loan and Reshuffles Board
Castle Biosciences (CSTL) has shared an announcement.
Castle Biosciences Announces Updates to Its Board of Directors
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Rodney Cotton has been appointed to its board of directors, effective immediately, and will stand for election at Castle's 2024 Annual Meeting of Stockholders, expected to be held in May 2024.
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
Company honored for creating an exceptional, people-first culture that empowers employees and fosters trust, transparency and authenticity Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through
Castle Biosciences(CSTL.US) Officer Sells US$128.51K in Common Stocks
$Castle Biosciences(CSTL.US)$ Officer MAETZOLD DEREK J sold 6,336 shares of Common Stocks on Mar 20, 21, 2024 at an average price of $20.28 for a total value of $128.51K.Source: Announcement What is s
Analysis
Price Target
No Data
